Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
Earnings Data
Report Date
Mar 17, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.22Last Year’s EPS
0.77Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue growth and improved margins. The FDA breakthrough designation adds further validation to GeneDx's technology. However, potential ASP declines and market underpenetration in NICUs were noted challenges. Overall, the highlights outweigh the lowlights, indicating a positive outlook.Company Guidance
Revenue Surge
GeneDx reported third quarter 2025 revenues of $116.7 million, a 52% increase year-over-year.
FDA Breakthrough Device Designation
The FDA granted breakthrough device designation to GeneDx's ExomeDx and GenomeDx tests, validating the company's technology as a gold standard in transforming lives.
Strong Genetic Testing Growth
Exome and genome revenue increased by 66% from the same quarter last year. GeneDx reported 25,702 exome and genome tests, with growth accelerating from 24% in Q1 to 33% in Q3.
Improved Gross Margins
GeneDx expanded total company adjusted gross margin to 74% due to favorable mix shift, improved reimbursement, and lower COGS.
Raising Revenue Guidance
GeneDx raised their 2025 revenue guidance to between $425 million and $428 million, and expects exome and genome revenue growth between 53% and 55% for the full year.
WGS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
WGS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 28, 2025 | $130.66 | $137.47 | +5.21% |
Jul 29, 2025 | $84.91 | $91.78 | +8.09% |
Apr 30, 2025 | $116.97 | $66.85 | -42.85% |
Feb 18, 2025 | $76.35 | $112.76 | +47.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GeneDx Holdings (WGS) report earnings?
GeneDx Holdings (WGS) is schdueled to report earning on Mar 17, 2026, After Close (Confirmed).
What is GeneDx Holdings (WGS) earnings time?
GeneDx Holdings (WGS) earnings time is at Mar 17, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WGS EPS forecast?
WGS EPS forecast for the fiscal quarter 2025 (Q4) is 0.22.